DV
Dividend Vision

AQST Stock — Aquestive Therapeutics Inc

Aquestive Therapeutics Inc (AQST)

Updated November 12, 2026.

AQST is a stock. Total return is -77.8% over the past 8.3 years, 279.6 points behind SPY at 201.8%.

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes specialty medications delivered through proprietary film formulations, primarily for central nervous system disorders, opioid dependence, and other acute conditions. Its marketed products include Libervant for seizure treatment, Suboxone for opioid dependence, SYMPAZAN for rare epilepsy, KYNMOBI for Parkinson's disease, and AZSTARYS for ADHD, with additional candidates in clinical development. The company does not currently distribute to shareholders.

AQST performance versus SPY

Total return is -77.8% over the past 8.3 years, 279.6 points behind SPY at 201.8%. Over the past year its total return — price change plus distributions reinvested — is -36.0%. Its deepest 1-year drawdown was 55.4%.

WindowTotal returnCAGR
1M-25.8%—
3M-15.6%—
6M-14.2%—
YTD-44.7%—
1Y-36.0%—
2Y CAGR—-15.40%
3Y CAGR—28.50%
5Y CAGR—-10.70%
Since inception 2018-07-25 · 8.3 years-77.8%-16.60%

AQST key facts

Asset type
Stock
Asset class
Equity
Inception date
07/25/2018
Distribution frequency
None
Last close
$3.57 (as of 2026-11-12)
Market cap
$448,076,583
Average volume
2,792,922
Beta
1.505
Payout ratio
0.0%
EPS
-$0.66

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AQST risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.4%.

Who may consider AQST — and who may not

It is a weaker fit for investors who need monthly cash flow (AQST does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AQST

Tagged: Healthcare.

Frequently asked questions

Does AQST pay monthly?

No. AQST does not currently distribute.

When does AQST pay a dividend?

AQST does not currently distribute.

How has AQST performed?

Total return is -77.8% over the past 8.3 years, 279.6 points behind SPY at 201.8%. Over the past year its total return — price change plus distributions reinvested — is -36.0%. Its deepest 1-year drawdown was 55.4%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.